文献速递白血病

德国慢性髓性白血病患者治疗期望与目标:以患者为中心的视角

Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective.
PubMed 文献 · Leukemia · 2025-12-19

该研究在德国CML患者中开展全国性在线调查,评估诊断时、治疗期间及无治疗缓解阶段的治疗目标。582例患者完成问卷,中位年龄56岁,48.8%为女性。结果提示患者 priorities 在深度分子学缓解与最佳耐受性之间存在分歧,将患者报告的偏好纳入共享决策可能改善满意度、依从性和长期结局。

要点

  • TKI总体耐受性获正面评价(中位4/5),一线治疗及病程较短者评价更高。
  • 年轻患者(<45岁)更关注生育、性健康和工作相关问题。
  • 有停药经验者更愿意为缓解前景接受不良反应。

核心结论

  • 患者 priorities 在实现深度分子学缓解与维持最佳耐受性之间存在分歧。
  • 将患者报告的偏好整合入共享决策可能提升CML患者的满意度、依从性和长期结局。

研究设计与样本

  • 研究为德国全国性在线调查,由研究者与德国CML联盟及患者组织合作开展。
  • 问卷包含治疗满意度、进展恐惧和生活质量优先级的验证量表,并补充新开发条目。

主要发现

  • TKI总体耐受性评分中位为4/5,一线治疗和病程较短患者评价更积极,长期生存者报告更多日常生活限制。
  • 年轻患者(<45岁)强调生育、性健康和工作相关顾虑,老年患者优先考虑耐受性、独立性和心理健康。
  • 有停药经历的患者更愿意为缓解前景接受不良反应。

临床怎么用

  • 临床决策中应主动评估并纳入患者个人治疗目标和优先级。
  • 对年轻患者需关注生育、性健康和工作相关问题,对老年患者关注耐受性、独立性和心理健康。
  • 对有停药意愿或经验的患者,可讨论为实现无治疗缓解而接受不良反应的意愿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia (CML) is a chronic condition with excellent long-term survival under tyrosine kinase inhibitor (TKI) therapy. However, patient priorities regarding treatment goals and quality of life remain insufficiently understood. We conducted a nationwide online survey among German CML patients in collaboration with the German CML Alliance and patient organizations to assess treatment goals at diagnosis, during therapy, and in the treatment-free remission phase. The questionnaire included validated measures of treatment satisfaction, fear of progression, and quality-of-life priorities, supplemented by newly developed items. Between November 2024 and February 2025, 582 patients (median age 56 years, 48.8% female) completed the survey. Overall TKI tolerability was rated positively (median 4/5), particularly in first-line therapy and among patients with shorter disease duration, whereas long-term survivors reported more daily-life limitations. Younger patients ( < 45 years) emphasized fertility, sexuality, and work-related concerns, while older patients prioritized tolerability, independence, and mental health. Treatment history shaped expectations: those with discontinuation experience were more willing to accept adverse effects for the prospect of remission. Overall, patient priorities diverged between achieving deep molecular response and maintaining optimal tolerability. Integrating patient-reported preferences into shared decision-making may enhance satisfaction, adherence, and long-term outcomes of patients with CML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Ernst P, Lohse C, Lauseker M, et al. Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective. Leukemia. 2025. PMID: 41419606. doi:10.1038/s41375-025-02826-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。